Oncology

Cancer is characterized by uncontrolled cell growth. In some cases, cancer can metastasize i.e., spread to different parts of the body. It is one of the deadliest diseases and requires immediate medical attention. Despite the availability of several anticancer drugs (oncology drugs), a lot is yet to be discovered.

Oncology is the branch of medicine that deals with the prevention, diagnosis, and treatment of cancer. Alkem has dedicated a division for anticancer products, which is christened ‘Oncology Division’. The Oncology division has been in existence for over 17 years. As far as anticancer medicines are concerned, Alkem Oncology has hormonal preparations, cytotoxic drugs, and targeted therapeutic drugs in its portfolio.

Alkem Oncology offers three biosimilar drugs i.e., Rituximab (Cytomab), Bevacizumab (Advamab), and Trastuzumab (Hersima). All of these are monoclonal antibodies. Rituximab is highly recommended by oncologists as the targeted therapy for the treatment of non-Hodgkin lymphoma (NHL) and autoimmune disorders like rheumatoid arthritis (RA). Bevacizumab is used as a targeted therapy in the advanced stages of colorectal cancer and recurrent ovarian cancer.

Trastuzumab is used as a targeted therapy in HER2 +ve Breast Cancer and HER2 +ve Gastric Cancer. Enzene Biosciences, a dedicated research unit of Alkem Laboratories, is currently working on a number of monoclonal antibodies. Also, there are several other biosimilar drugs in the pipeline. Alkem Oncology offers three biosimilar drugs i.e. Rituximab (Oncology), Bevacizumab (Advamab), and Trastuzumab (Hersima). All of these are monoclonal antibodies.

Rituximab is highly recommended by oncologists as targeted therapy for the treatment of one of the cancers non-Hodgkin lymphoma (NHL) and autoimmune disorders like rheumatoid arthritis (RA).

Bevacizumab is used as a targeted therapy in advanced stages of Colorectal Cancer & Recurrent Ovarian Cancer.

Trastuzumab is used as a targeted therapy in HER2 +ve Breast Cancer & HER2 +ve Gastric Cancer Enzene Biosciences, a dedicated research unit of Alkem Laboratories, is currently working on a number of monoclonal antibodies. Also, there are several other biosimilar drugs that are in the pipeline.

Enzene Biosciences, a dedicated research unit of Alkem Laboratories, is currently working on a number of monoclonal antibodies. Also, there are several other biosimilar drugs in the pipeline.